PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Programmed cell death protein 1 (PD-1) is an immune checkpoint receptor that is upregulated on activated T cells for the induction of immune tolerance. Tumour cells frequently overexpress the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from the immune system. Monoclonal antibodies that block the interaction between PD-1 and PD-L1, by binding to either the ligand or receptor, have shown notable clinical efficacy in patients with a variety of cancers, including melanoma, colorectal cancer, non-small-cell lung cancer and Hodgkin's lymphoma. Although it is well established that PD-1-PD-L1 blockade activates T cells, little is known about the role that this pathway may have in tumour-associated macrophages (TAMs). Here we show that both mouse and human TAMs express PD-1. TAM PD-1 expression increases over time in mouse models of cancer and with increasing disease stage in primary human cancers. TAM PD-1 expression correlates negatively with phagocytic potency against tumour cells, and blockade of PD-1-PD-L1 in vivo increases macrophage phagocytosis, reduces tumour growth and lengthens the survival of mice in mouse models of cancer in a macrophage-dependent fashion. This suggests that PD-1-PD-L1 therapies may also function through a direct effect on macrophages, with substantial implications for the treatment of cancer with these agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“and treatment with checkpoint inhibitors targeting PD-1 or PD-L1 increases phagocytosis and reduces tumor growth [329].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“In human and mouse CRC tumor models, high levels of PD-1 expression on TAM have low tumor phagocytosis”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [329]
In the citing paper
“Tumor-associated macrophages were also recently shown to express PD-1 in both mice and humans with colorectal cancer and to impair macrophage phagocytosis (59).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [59]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Tumour-educated macrophages promote tumour progression and metastasis
Pollard, J. W. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1256 · Cited by 3,367
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Cited by
Items 401–500 of 1,001
Innate and acquired immune surveillance in the postdissemination phase of metastasis
Gonzalez, H., Robles, I., & Werb, Z. (2018) · The FEBS Journal · doi:10.1111/febs.14325 · Cited by 77
Research Progress on Tumor‐Associated Macrophages and Inflammation in Cervical Cancer
Liu, Y., Li, L., Li, Y., & Zhao, X. (2020) · BioMed Research International · doi:10.1155/2020/6842963 · Cited by 83
You, L., Zhao, Y., Kuča, K., Wang, X., Olekšák, P., Chrienová, Ž., Nepovimová, E., Jacevic, V. M., Wu, Q., & Wu, W. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03030-2 · Cited by 81
Interaction between intestinal microbiota and tumour immunity in the tumour microenvironment
Yang, X., Guo, Y., Chen, C., Shao, B., Zhao, L., Zhou, Q., Liu, J., Wang, G., Yuan, W., & Sun, Z. (2021) · Immunology · doi:10.1111/imm.13397 · Cited by 86
A vaccine-based nanosystem for initiating innate immunity and improving tumor immunotherapy
Zheng, D., Gao, F., Qian, C., Bao, P., Dong, X., Fan, J., Song, W. L., Zeng, X., Cheng, S., & Zhang, X. (2020) · Nature Communications · doi:10.1038/s41467-020-15927-0 · Cited by 80
Wang, Z., Hao, C., Zhuang, Q., Zhan, B., Sun, X., Huang, J., Cheng, Y., & Zhu, X. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.563784 · Cited by 77
Wang, I., Song, L., Wang, B. Y., Kalebasty, A. R., Uchio, E., & Zi, X. (2022) · PubMed · Cited by 111
Zhang, C., Wei, S., Dai, S., Li, X., Wang, H., Zhang, H., Sun, G., Shan, B., & Zhao, L. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-006230 · Cited by 90
Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma
Liu, W. R., & Shipp, M. A. (2017) · Blood · doi:10.1182/blood-2017-06-781989 · Cited by 82
Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells
Menter, T., & Tzankov, A. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00054 · Cited by 84
Ryan, N. M., Anderson, K., Volpedo, G., Hamza, O., Varikuti, S., Satoskar, A. R., & Oghumu, S. (2019) · International Journal of Cancer · doi:10.1002/ijc.32781 · Cited by 79
Tumor cells induce LAMP2a expression in tumor-associated macrophage for cancer progression
Wang, R., Liu, Y., Liu, L., Chen, M., Wang, X., Yang, J., Gong, Y., Ding, B.-S., Wei, Y., & Wei, X. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.045 · Cited by 74
Lorenzo-Sanz, L., & Muñoz, P. (2019) · Cancer Microenvironment · doi:10.1007/s12307-019-00232-2 · Cited by 86
The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy
Neophytou, C. M., Pierides, C., Christodoulou, M., Costeas, P., Kyriakou, T.-C., & Papageorgis, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00899 · Cited by 83
Phagocytosis increases an oxidative metabolic and immune suppressive signature in tumor macrophages
Gonzalez, M. A., Lu, D., Yousefi, M., Kroll, A. V., Lo, C. H., Briseño, C. G., Watson, J. E. V., Novitskiy, S. V., Arias, V., Zhou, H., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221472 · Cited by 82
Shen, W., Shi, P., Dong, Q., Zhou, X., Chen, C., Sui, X., Tian, W., Zhu, X., Wang, X., Jin, S., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007068 · Cited by 79
He, J., Zhou, Y. L., & Sun, L. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-023-01438-0 · Cited by 84
Moore, J. A., Mistry, J. J., Hellmich, C., Horton, R. H., Wojtowicz, E. E., Jibril, A., Jefferson, M., Wileman, T., Beraza, N., Bowles, K. M., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci153157 · Cited by 71
Tumor-Associated Macrophages in Hepatocellular Carcinoma: Friend or Foe?
Zhou, D., Luan, J., Huang, C., & Li, J. (2020) · Gut and Liver · doi:10.5009/gnl20223 · Cited by 78
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
The PD-1:PD-L1 axis in Inflammatory Arthritis
Canavan, M., Floudas, A., Veale, D. J., & Fearon, U. (2021) · BMC Rheumatology · doi:10.1186/s41927-020-00171-2 · Cited by 82
Wang, Y., Wang, Z., Jia, F., Xu, Q., Shu, Z., Deng, J., Li, A., Yu, M., & Yu, Z. (2022) · Bioactive Materials · doi:10.1016/j.bioactmat.2022.01.003 · Cited by 85
Shekarian, T., Zinner, C., Bartoszek, E. M., Duchemin, W., Wachnowicz, A. T., Hogan, S. A., Etter, M. M., Flammer, J., Paganetti, C., Martins, T. A., et al. (2022) · Science Advances · doi:10.1126/sciadv.abn9440 · Cited by 79
Lee, H., Guo, Y., Ross, J., Schoen, S. J., Degertekin, F. L., & Arvanitis, C. (2022) · Science Advances · doi:10.1126/sciadv.add2288 · Cited by 75
Targeting macrophages: a novel treatment strategy in solid tumors
Liu, M., Liu, L., Song, Y., Li, W., & Xu, L. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03813-w · Cited by 77
Diversity of immune checkpoints in cancer immunotherapy
Guo, Z., Zhang, R., Yang, A., & Zheng, G. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1121285 · Cited by 83
Liu, H.-J., Lizotte, P. H., Du, H., Speranza, M. C., Lam, H. C., Vaughan, S. W., Alesi, N., Wong, K., Freeman, G. J., Sharpe, A. H., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.98674 · Cited by 78
The Tumor Microenvironment in Colorectal Cancer Therapy
Pedrosa, L., Esposito, F., Thomson, T. M., & Maurel, J. (2019) · Cancers · doi:10.3390/cancers11081172 · Cited by 69
Targeting CD47 as a cancer therapeutic strategy: the cutaneous T-cell lymphoma experience
Folkes, A. S., Feng, M., Zain, J. M., Abdulla, F., Rosen, S. T., & Querfeld, C. (2018) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000468 · Cited by 72
c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth
Lyle, C., Richards, S., Yasuda, K., Napoleon, M. A., Walker, J., Arinze, N. V., Belghasem, M., Vellard, I., Yin, W., Ravid, J. D., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-56208-1 · Cited by 72
Li, J., Liu, X.-G., Ge, R., Yin, Y., Liu, Y.-D., Lu, W.-P., Huang, M., He, X.-Y., Wang, J., Cai, G., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01634-7 · Cited by 76
Beck, J. D., Diken, M., Suchan, M., Streuber, M., Diken, E., KOLB, L. D., Allnoch, L., Vascotto, F., Peters, D., Beißert, T., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.02.013 · Cited by 78
Wang, Y., Ma, R., Liu, F., Lee, S. A., & Zhang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00374 · Cited by 71
“More recently, it was found that interaction of PD-L1 with PD-1 expressed on tumor-associated macrophages inhibits the phagocytic potency of macrophages against tumor cells (33).”
BackgroundGlioblastoma multiforme: novel therapeutic targets
Muir, M. T., Gopakumar, S., Traylor, J. I., Lee, S., & Rao, G. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1762568 · Cited by 76
Gago-Domínguez, M., Matabuena, M., Redondo, C. M., Patel, S. P., Carracedo, Á., Ponte, S. M., Martínez, M. E., & Castelao, J. E. (2020) · Scientific Reports · doi:10.1038/s41598-020-70077-z · Cited by 79
Metabolic reprogramming in the immunosuppression of tumor-associated macrophages
Wang, Y., Wang, D., Yang, L., & Zhang, Y. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002426 · Cited by 79
Li, B., Song, T., Wang, F., Yin, C., Li, Z., Lin, J.-P., Meng, Y., Feng, H., & Jing, T. (2019) · Oncogenesis · doi:10.1038/s41389-019-0126-2 · Cited by 73
Tsai, M.-S., Chen, W.-C., Lu, C.-H., & Chen, M.-F. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.02.027 · Cited by 70
Sensing and clearance of apoptotic cells
Nagata, S., & Segawa, K. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.07.007 · Cited by 71
Zhao, L., Zheng, R., Rao, X., Huang, C., Zhou, H., Yu, X., Jiang, X., & Li, S. (2024) · Advanced Science · doi:10.1002/advs.202309204 · Cited by 90
Peritumoral brain zone in glioblastoma: biological, clinical and mechanical features
Ballestín, A., Armocida, D., Ribecco, V., & Seano, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1347877 · Cited by 81
Porta, C., Sica, A., & Riboldi, E. (2018) · The FEBS Journal · doi:10.1111/febs.14288 · Cited by 69
Imaging and therapy of ovarian cancer: clinical application of nanoparticles and future perspectives
Lorenzo, G. D., Ricci, G., Severini, G. M., Romano, F., & Biffi, S. (2018) · Theranostics · doi:10.7150/thno.26345 · Cited by 72
Li, Y., Wu, H. C., Ji, B., Qian, W., Xia, S., Wang, L., Xu, Y., Chen, J., Yang, L. P. H., & Mao, H. Z. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00368 · Cited by 75
Clinical Development of Colony-Stimulating Factor 1 Receptor (CSF1R) Inhibitors
Lin, C. (2021) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-20-32 · Cited by 69
Lü, Y., Huntoon, K. M., Lee, D., Wang, Y., Ha, J., Qie, Y., Li, X., Schrank, B. R., Dong, S., Gallup, T. D., et al. (2022) · Nature Nanotechnology · doi:10.1038/s41565-022-01245-7 · Cited by 72
Targeted glycan degradation potentiates cellular immunotherapy for solid tumors
Wu, J., Wang, X., Huang, Y., Zhang, Y., Su, S., Shou, H., Wang, H., Zhang, J., & Wang, B. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2300366120 · Cited by 76
Notch Signaling in Macrophages in the Context of Cancer Immunity
Palaga, T., Wongchana, W., & Kueanjinda, P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00652 · Cited by 72
Lu, Q., Sun, Q., Li, P., Yang, L., Yang, S., Wang, Y., Cheng, Y. S., Song, Y., Wang, S., Tan, F., et al. (2019) · Journal of Materials Chemistry B · doi:10.1039/c9tb00089e · Cited by 71
Wu, H., Zhang, X., Han, D., Cao, J., & Tian, J. (2020) · PeerJ · doi:10.7717/peerj.8721 · Cited by 74
Nam, S., Lee, A., Lim, J., & Lim, J.-S. (2019) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2018.201 · Cited by 68
The unique immune microenvironment of liver metastases: Challenges and opportunities
Ciner, A., Jones, K. I., Muschel, R. J., & Brodt, P. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.003 · Cited by 79
Exosomes: A Potential Therapeutic Tool Targeting Communications between Tumor Cells and Macrophages
Guo, W., Li, Y., Pang, W., & Shen, H. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.003 · Cited by 75
Yan, C. W., Yang, J., Saleh, N., Chen, S., Ayers, G. D., Abramson, V. G., Mayer, I. A., & Richmond, A. J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105207 · Cited by 77
Luo, X., Hu, D., Gao, D., Wang, Y., Chen, X., Liu, X., Zheng, H., Sun, M., & Sheng, Z. (2021) · ACS Nano · doi:10.1021/acsnano.1c01608 · Cited by 70
Tumor‑associated macrophages in lung cancer: Friendly or evil? (Review)
Xu, F., Wei, Y., Tang, Z., Liu, B., & Dong, J. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.11518 · Cited by 67
“The TaMs upregulate the expression of Pd-l1 to suppress T-cell toxicity and inhibit phagocytosis (5,62).”
BackgroundDegroote, H., Vandierendonck, A., Geerts, A. M., Vlierberghe, H. V., & Devisscher, L. (2018) · Journal of Immunology Research · doi:10.1155/2018/7819520 · Cited by 69
Fujiwara, Y., Mittra, A., Naqash, A. R., & Takebe, N. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2020.11 · Cited by 87
Amodio, V., Mauri, G., Reilly, N. M., Bianchi, A. S., Siena, S., Bardelli, A., & Germano, G. (2021) · Cancers · doi:10.3390/cancers13112638 · Cited by 74
Davies, D., Kamdar, S., Woolf, R., Zlatareva, I., Iannitto, M. L., Morton, C., Haque, Y., Martin, H., Biswas, D., Ndagire, S., et al. (2024) · Nature Cancer · doi:10.1038/s43018-023-00690-0 · Cited by 76
Holzgruber, J., Martins, C. P., Kulcsár, Z., Duplaine, A., Rasbach, E., Migayron, L., Singh, P. K., Statham, E., Landsberg, J., Boniface, K., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51496-2 · Cited by 78
Stromnes, I. M., Burrack, A. L., Hulbert, A., Bonson, P., Black, C., Brockenbrough, J. S., Raynor, J. F., Spartz, E. J., Pierce, R. H., Greenberg, P. D., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0448 · Cited by 66
A functional subset of CD8+ T cells during chronic exhaustion is defined by SIRPα expression
Myers, L. M., Tal, M. C., Torrez Dulgeroff, L. B., Carmody, A. B., Messer, R. J., Gulati, G., Yiu, Y. Y., Staron, M. M., Angel, C. L., Sinha, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-08637-9 · Cited by 66
Self-citationBispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity
Kotanides, H., Li, Y., Malabunga, M., Carpenito, C., Eastman, S. W., Shen, Y., Wang, G., Inigo, I., Surguladze, D., Pennello, A. L., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0304 · Cited by 65
Tumor associated macrophage and microbe: The potential targets of tumor vaccine delivery
Jiang, J., Mei, J., Yi, S., Feng, C., Ma, Y., Liu, Y., Liu, Y., & Chen, C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114046 · Cited by 72
Matteis, R. D., Flak, M. B., Gonzalez-Nuñez, M., Austin‐Williams, S., Palmas, F., Colas, R. A., & Dalli, J. (2022) · Science Advances · doi:10.1126/sciadv.abl5420 · Cited by 70
Fan, Q., Kuang, L., Wang, F., Yin, Y., Dong, Z., Tian, N., Wang, J., Yin, T., & Wang, Y. (2024) · ACS Nano · doi:10.1021/acsnano.4c01253 · Cited by 70
Lin, C., Ren, W., Luo, Y., Li, S., Chang, Y., Li, L., Xiong, D., Huang, X., Xu, Z., Zeng, Y., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0628 · Cited by 71
Rezasoltani, S., Yadegar, A., Aghdaei, H. A., & Zali, M. R. (2020) · Cancer Medicine · doi:10.1002/cam4.3694 · Cited by 72
Kaur, S., Cicalese, K. V., Banerjee, R., & Roberts, D. D. (2020) · Antibody Therapeutics · doi:10.1093/abt/tbaa017 · Cited by 79
Macrophages and microglia in inflammation and neuroinflammation underlying different pain states
Ouyang, C., Luo, X., & Ji, R. (2023) · Medical Review · doi:10.1515/mr-2023-0034 · Cited by 74
Subramanian, A., Nemat‐Gorgani, N., Ellis-Caleo, T. J., van IJzendoorn, D. G. P., Sears, T. J., Somani, A., Luca, B. A., Zhou, M. Y., Bradić, M., Torres, I. A., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00743-y · Cited by 73
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Hantel, A., Gabster, B. P., Cheng, J. X., Golomb, H. M., & Gajewski, T. F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0384-0 · Cited by 65
Friend or Foe? Recent Strategies to Target Myeloid Cells in Cancer
Chaib, M., Chauhan, S. C., & Makowski, L. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00351 · Cited by 67
Scavenger receptor MARCO contributes to macrophage phagocytosis and clearance of tumor cells
Xing, Q., Feng, Y., Sun, H., Yang, S., Sun, T., Guo, X., Ji, F., Wu, B., & Zhou, D. (2021) · Experimental Cell Research · doi:10.1016/j.yexcr.2021.112862 · Cited by 68
Wu, L., Li, L., Li, S., Liu, L., Xin, W., Li, C., Yin, X., Xu, X., Bao, F., & Hua, Z. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.006 · Cited by 68
The role of lipid metabolism in tumor immune microenvironment and potential therapeutic strategies
Wang, D., Ye, Q., Gu, H., & Chen, Z. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.984560 · Cited by 74
Ma, H., Hu, T., Tao, W., Tong, J., Han, Z., Herndler‐Brandstetter, D., Wei, Z., Liu, R., Zhou, T., Liu, Q., et al. (2023) · Cell Research · doi:10.1038/s41422-023-00790-7 · Cited by 68
Zhao, J., Bang, S., Furutani, K., McGinnis, A., Jiang, C., Roberts, A., Donnelly, C. R., He, Q., James, M. L., Berger, M., et al. (2023) · Neuron · doi:10.1016/j.neuron.2023.05.022 · Cited by 67
Exosomal microRNA: a Novel Biomarker for Breast Cancer
He, Y., Deng, F., Yang, S., Wang, D., Chen, X., Zhong, S., Zhao, J., & Tang, J. (2017) · Biomarkers in Medicine · doi:10.2217/bmm-2017-0305 · Cited by 68
Shklovskaya, E., & Rizos, H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197139 · Cited by 73
Trametes robiniophila Murr: a traditional Chinese medicine with potent anti-tumor effects
Pan, J., Yang, C., Zhou, J., & Huang, J. (2019) · Cancer Management and Research · doi:10.2147/cmar.s193174 · Cited by 66
Cheruku, S., Rao, V., Pandey, R., Chamallamudi, M. R., Ravichandiran, V., & Kumar, N. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109569 · Cited by 67
Tricarboxylic acid cycle metabolites in the control of macrophage activation and effector phenotypes
Noe, J. T., & Mitchell, R. A. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.3ru1218-496r · Cited by 70
Wang, C., & Steinmetz, N. F. (2019) · Advanced Healthcare Materials · doi:10.1002/adhm.201801288 · Cited by 63
Hargadon, K. M. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.37 · Cited by 67
Hu, H., Zakharov, P. N., Peterson, O. J., & Unanue, E. R. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2019743117 · Cited by 67
mPGES-1 and ALOX5/-15 in tumor-associated macrophages
Weigert, A., Strack, E., Snodgrass, R. G., & Brüne, B. (2018) · Cancer and Metastasis Reviews · doi:10.1007/s10555-018-9731-3 · Cited by 70
Zhao, W., Hu, X., Li, W., Li, R., Chen, J., Zhou, L., Qiang, S., Wu, W., Shi, S., & Dong, C. (2021) · Small · doi:10.1002/smll.202007051 · Cited by 67
LSD1 silencing contributes to enhanced efficacy of anti-CD47/PD-L1 immunotherapy in cervical cancer
Xu, S., Wang, X., Yang, Y., Li, Y., & Wu, S. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03556-4 · Cited by 64
Dhanasekaran, R., Hansen, A. S., Park, J., Lemaitre, L., Lai, I. K., Adeniji, N., Kuruvilla, S. P., Suresh, A., Zhang, J., Swamy, V., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-0232 · Cited by 67
Sun, C., Yin, M., Cheng, Y., Kuang, Z., Liu, X., Wang, G., Wang, X., Yuan, K., Min, W., Dong, J., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01801 · Cited by 66
Clinical trials of self-replicating RNA-based cancer vaccines
Morse, M. A., Crosby, E. J., Force, J. M., Osada, T., Hobeika, A. C., Hartman, Z. C., Berglund, P., Smith, J., & Lyerly, H. K. (2023) · Cancer Gene Therapy · doi:10.1038/s41417-023-00587-1 · Cited by 62
Exosome-based nanoimmunotherapy targeting TAMs, a promising strategy for glioma
Luo, H., Zhang, H., Mao, J., Cao, H., Tao, Y., Zhao, G., Zhang, Z., Zhang, N., Liu, Z., Zhang, J., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05753-9 · Cited by 68
Liu, H., Deng, R., Zhu, C.-W., Han, H., Zong, G., Ren, L., Cheng, P., Wei, Z., Zhao, Y. W., Yu, S., et al. (2023) · Acta Pharmacologica Sinica · doi:10.1038/s41401-023-01158-8 · Cited by 63
Role of Tumor-Associated Macrophages in Sarcomas
Fujiwara, T., Healey, J. H., Ogura, K., Yoshida, A., Kondo, H., Hata, T., Kure, M., Tazawa, H., Nakata, E., Kunisada, T., et al. (2021) · Cancers · doi:10.3390/cancers13051086 · Cited by 64
Yang, S., Shim, M. K., Song, S., Cho, H., Choi, J., Jeon, S. I., Kim, W. J., Um, W., Park, J. H., Yoon, H. Y., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121841 · Cited by 63
Targeting Innate Immunity to Enhance the Efficacy of Radiation Therapy
Dar, T. B., Henson, R. M., & Shiao, S. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03077 · Cited by 65
Stoll, A., Bruns, H., Fuchs, M., Völkl, S., Nimmerjahn, F., Kunz, M., Peipp, M., Mackensen, A., & Mougiakakos, D. (2021) · Leukemia · doi:10.1038/s41375-021-01287-1 · Cited by 69
Herting, C. J., Karpovsky, I., & Lesinski, G. B. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-021-09988-w · Cited by 70
Metadata
- Authors
- Gordon, S. R., Maute, R. L., Dulken, B. W., Hutter, G., George, B. M., McCracken, M. N., Gupta, R., Tsai, J. M., Sinha, R., Corey, D., Ring, A. M., Connolly, A. J., & Weissman, I. L.
- Affiliations
- Stanford Medicine (US)
- Institute for Stem Cell Biology and Regenerative Medicine (US)
- Yale University (US)
- Corresponding author
- Weissman, Irving L.
- ORCID
- Venue
- Nature
- Published
- 2017-05
- Volume
- 545
- Issue
- 7655
- Pages
- 495-499
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC5931375
- OpenAlex
- W2615301036
- Cited by
- 2,247
- References
- 34
- Citations by year
- 2026: 167 · 2025: 261 · 2024: 303 · 2023: 298 · 2022: 309 · 2021: 299 · 2020: 264 · 2019: 158 · 2018: 135 · 2017: 51
- FWCI
- 75.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- National Science Foundation
- Cancer Research Institute
- A.P. Giannini Foundation
- Giannini Foundation of Agricultural Economics
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (155336)
- National Institutes of Health (1s10rr026780-01)
- National Cancer Institute (R01CA086017, P30CA124435)
- National Institute of General Medical Sciences (T32GM007365)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (T32AR050942)
- National Center for Research Resources (1S10RR02678001, 1S10RR026780, S10 RR026780)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
- Keywords
- PD-1, tumour-associated macrophages, PD-L1, phagocytosis, immune checkpoint blockade, tumour immunity, cancer immunotherapy, tumour-infiltrating macrophages
- MeSH terms
- Animals, Colonic Neoplasms, Disease Models, Animal, Female, Humans, Macrophages, Male, Mice, Inbred BALB C, Neoplasm Staging, Phagocytosis, Xenograft Model Antitumor Assays, Cell Line, Tumor, Cell Proliferation, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.